A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT05338775 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05338775
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-25
- Primary completion
- 2025-05-22
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.